ESPR Esperion Therapeutics Inc

Price (delayed)

$28.56

Market cap

$798.04M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.23

Enterprise value

$855.09M

Sector: Healthcare
Industry: Biotechnology

Highlights

ESPR's revenue has surged by 53% year-on-year and by 4% since the previous quarter
The company's gross profit has surged by 52% YoY and by 3.2% QoQ
Esperion Therapeutics's debt has surged by 170% YoY and by 103% QoQ
The net income has contracted by 48% YoY and by 42% from the previous quarter

Key stats

What are the main financial stats of ESPR
Market
Shares outstanding
27.94M
Market cap
$798.04M
Enterprise value
$855.09M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.76
Earnings
Revenue
$227.55M
EBIT
-$120.88M
EBITDA
-$120.33M
Free cash flow
-$86.05M
Per share
EPS
-$5.23
Free cash flow per share
-$3.13
Book value per share
-$3.45
Revenue per share
$8.28
TBVPS
$12.86
Balance sheet
Total assets
$353.26M
Total liabilities
$449.39M
Debt
$362.01M
Equity
-$96.13M
Working capital
$251.83M
Liquidity
Debt to equity
-3.77
Current ratio
3.68
Quick ratio
3.24
Net debt/EBITDA
-0.47
Margins
EBITDA margin
-52.9%
Gross margin
98.9%
Net margin
-63.1%
Operating margin
-53.3%
Efficiency
Return on assets
-51.5%
Return on equity
N/A
Return on invested capital
-69.4%
Return on capital employed
-46.6%
Return on sales
-53.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ESPR stock price

How has the Esperion Therapeutics stock price performed over time
Intraday
2.44%
1 week
-4.83%
1 month
10.14%
1 year
-54.57%
YTD
9.85%
QTD
9.85%

Financial performance

How have Esperion Therapeutics's revenue and profit performed over time
Revenue
$227.55M
Gross profit
$225.16M
Operating income
-$121.4M
Net income
-$143.55M
Gross margin
98.9%
Net margin
-63.1%
ESPR's revenue has surged by 53% year-on-year and by 4% since the previous quarter
The company's gross profit has surged by 52% YoY and by 3.2% QoQ
The net income has contracted by 48% YoY and by 42% from the previous quarter
The company's operating income fell by 43% QoQ and by 30% YoY

Growth

What is Esperion Therapeutics's growth rate over time

Valuation

What is Esperion Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
3.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.76
Esperion Therapeutics's EPS has decreased by 46% YoY and by 41% QoQ
The price to sales (P/S) is 93% lower than the last 4 quarters average of 48.9
ESPR's revenue has surged by 53% year-on-year and by 4% since the previous quarter

Efficiency

How efficient is Esperion Therapeutics business performance
Esperion Therapeutics's return on sales has decreased by 40% QoQ but it has increased by 12% YoY
The return on invested capital has grown by 35% year-on-year but it has declined by 3.6% since the previous quarter
The return on assets has declined by 34% year-on-year and by 24% since the previous quarter

Dividends

What is ESPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ESPR.

Financial health

How did Esperion Therapeutics financials performed over time
The total assets is 21% less than the total liabilities
ESPR's total liabilities has surged by 131% year-on-year and by 86% since the previous quarter
The total assets has soared by 65% YoY and by 41% from the previous quarter
Esperion Therapeutics's debt has surged by 170% YoY and by 103% QoQ
ESPR's debt to equity has dropped by 156% year-on-year and by 119% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.